Just came across an interesting story about a major oversight by novo nordisk that probably opening a door for generic
tldr: Novo Nordisk let their semaglutide patent lapse in Canada - the world's 2nd largest semaglutide market - apparently over a $250 annual maintenance fee. now generics are coming.
What happened:
- Novo filed a patent for semaglutide in Canada like they did everywhere else
- They paid maintenance fees through 2018, then just... stopped
- There's even a paper trail showing their lawyers asked for a $250 refund in 2017 because they "needed more time to decide" if they wanted to keep paying
- The patent lapsed, and now generic companies are waiting for approval once data exclusivity expires (expected Q1 2025)
so yeah.. we are getting generic ozempic sooner than expcted
